Detalles de la búsqueda
1.
Returning to work in lung cancer survivors-a multi-center cross-sectional study in Germany.
Support Care Cancer
; 29(7): 3753-3765, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-33211206
2.
Use of psychosocial services by lung cancer survivors in Germany : Results of a German multicenter study (LARIS).
Strahlenther Onkol
; 195(11): 1018-1027, 2019 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-31292665
3.
Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer.
Eur Respir J
; 46(1): 219-29, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25792638
4.
Psychological distress in lung cancer survivors at least 1 year after diagnosis-Results of a German multicenter cross-sectional study.
Psychooncology
; 27(8): 2002-2008, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29761591
5.
Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study.
Lancet Oncol
; 12(8): 795-805, 2011 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-21782507
6.
Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice.
Ther Adv Med Oncol
; 13: 17588359211012361, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33995597
7.
Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab.
Oncol Lett
; 17(6): 4891-4900, 2019 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-31186697
8.
Quality of Life in NSCLC Survivors - A Multicenter Cross-Sectional Study.
J Thorac Oncol
; 14(3): 420-435, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30508641
9.
ERCC1 assessment in upfront treatment with and without cisplatin-based chemotherapy in stage IIIB/IV non-squamous non-small cell lung cancer.
Med Oncol
; 35(7): 106, 2018 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-29905882
10.
A phase II study of irinotecan (CPT-11) and carboplatin in patients with limited disease small cell lung cancer (SCLC).
Lung Cancer
; 57(2): 181-6, 2007 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-17442447
11.
Dysfunctional inhibitory muscarinic receptors mediate enhanced histamine release in isolated human bronchi.
Life Sci
; 80(24-25): 2294-7, 2007 May 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-17320912
12.
65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer.
Lung Cancer (Auckl)
; 8: 217-229, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-29158696
13.
Comprehensive Biomarker Analyses in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer Prospectively Treated with the Polo-Like Kinase 1 Inhibitor BI2536.
Oncol Res Treat
; 40(7-8): 435-439, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28628916
14.
Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial.
Clin Cancer Res
; 11(2 Pt 1): 690-6, 2005 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-15701857
15.
The gefitinib long-term responder (LTR)--a cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP).
Lung Cancer
; 77(1): 183-91, 2012 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-22483783
16.
The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial.
J Thorac Oncol
; 5(7): 1060-7, 2010 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-20526206
17.
Highly focused T cell responses in latent human pulmonary Mycobacterium tuberculosis infection.
J Immunol
; 174(4): 2174-84, 2005 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-15699149
18.
Longitudinal analysis of Mycobacterium tuberculosis 19-kDa antigen-specific T cells in patients with pulmonary tuberculosis: association with disease activity and cross-reactivity to a peptide from HIVenv gp120.
Eur J Immunol
; 33(6): 1613-23, 2003 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-12778479
Resultados
1 -
18
de 18
1
Próxima >
>>